Just in 👉data from SWOG Cancer Research Network 1216 trial in mHSPC#prostatecancer👉 PSA level at 3 and 7 months after starting ADT Rx are strongly prognostic of OS: It’s time to design de- or escalation trials based on response biomarkers. OPEN access👉 tinyurl.com/3azhpt4r OncoAlert UroToday.com

Pleased to share our latest work published in Urologic Oncology focusing on precision medicine in #ProstateCancer

Link 👇
authors.elsevier.com/c/1iwC7_OWv~Zu…

Anis Hamid Christopher Sweeney, MBBS
Peter Mac Research

Andrei Gafita uses his prior The Lancet Oncology LuPSMA nomogram to analyse the #TheraP study... Results here:
euoncology.europeanurology.com/article/S2588-…

'We found that the statistical models can predict patient survival, and aid in determining whether Lu-PSMA therapy or cabazitaxel yields a higher

Thanks to Radiology for the opportunity to share our review on emerging theranostics for prostate cancer and a model of PSMA therapy ProsTIC

Peter Mac Cancer Centre Michael Hofman Arun Azad Declan Murphy Liz Medhurst Annette Van Der Heyden Jeremy Ong SidneyLevy David Chen

Thanks European Urology it's an honour to review for the #1 ranked Urology journal. The EU family of journals has made a huge impact on GU oncology.

GU Cast | Urology podcast! Shankar Siva Michael Hofman Renu Eapen Edmond Kwan Peter Mac Cancer Centre

(Thanks also for supporting a lot of our work over many years!)

Congratulations to our April Reviewer of the Month Arun Azad!

Thank you for your continued support to European Urology!

#UroSoMe #MedTwitter #ROTM

Thanks for the opportunity to present these data on UroToday.com

Link to manuscript and Tweetorial - x.com/azadoncology/s…

eBioMedicine – The Lancet Discovery Science Peter Mac Cancer Centre Predicine, Inc.

“Genomic markers can indicate poor prognosis to LuPSMA, including AR and PTEN mutations. With its half life, ctDNA level changes rapidly in response to LuPSMA.

Thank you to Dr. Heidi Fettke PhD on her in-depth research into the practical use of ctDNA! 🧬

#ProsTIC24

Arun Azad UroToday.com Great talk Arun and Alicia. Really innovative study 👏🏼

Arun Azad UroToday.com Great discussion of the #LIBERTAS study! Thank you Alicia Morgans, MD, MPH and Arun Azad. LIBERTAS is breaking new ground in a number of places, including scientific ones and also in breaking barriers regarding inclusivity of gender diverse patients. Great interview. #MyCompany

urotoday.com/video-lectures… via UroToday.com

A myriad of trials are now assessing the combination of #LuPSMA and other anti cancer agents.

💡💬🤔 Questions remains: does survival and durability increase with combination tx?

Thank you Prof Arun Azad for the comprehensive talk at #ProsTIC24

Our latest manuscript in eBioMedicine – The Lancet Discovery Science looking at DNA damage response (DDR) alterations in #ctDNA from a large cohort of mCRPC #prostatecancer pts.

Weblink: rb.gy/zy3e8

Thanks to pts, families, investigators, Predicine, Inc., Manish Kohli, Dr Heidi Fettke (1/9)

Our latest on ctDNA% in mCRPC in Nature Communications: we affirm the independent strong prognostic implications & present a tool for predicting pre-blood draw whether ctDNA% is sufficiently high for genomic biomarker testing (e.g. BRCA2). Thread 👇. 1/n nature.com/articles/s4146…

BRCA-deficient metastatic #ProstateCancer has an adverse Prognosis and distinct genomic phenotype. #BeyondTheAbstract on UroToday > bit.ly/48ShKE9 Arun Azad eBioMedicine – The Lancet Discovery Science Peter Mac Cancer Centre

Only 2.5 weeks to go! Registration still available. The most important #PSMA education event for 2024. Join 300+ people from 20+ countries in #melbourne prostic24.org Michael Hofman Prostate Cancer Foundation Peter Mac Cancer Centre Peter Mac Research GU Cast | Urology podcast! Arun Azad

Peninsula Health found guilty of junior doctor wage theft. Now it is appealing the decision.

Who's decision was it to appeal? Was it the executive, the legal officer, their legal team, the board, or the government?
news.com.au/finance/work/a…

The #PSMA who's who are coming to #Melbourne in less than 4 weeks! Still time to register. Over 300 delegates from 20+ countries. Come on 🫵 prostic24.org/registration Michael Hofman Ken Herrmann Heather Jacene PCF Science Louise Emmett Peter Mac Cancer Centre Peter Mac Research GU Cast | Urology podcast!

During a panel discussion at SCOPE, Shir N, part of our J&J Innovative Medicine Global Medical Affairs team, spoke about the approaches we have been taking around inclusivity of LGBTQIA+ individuals in our clinical trials & in particular the #LIBERTAS study.
clinicaltrialsarena.com/news/inclusivi…

Our Terbium-161 PSMA clinical trial reached full recruitment today, 10 months ahead of schedule. Incredible effort by Peter Mac Cancer Centre and collaboration with Isotopia Molecular Imaging and PCF Science

#TeamScience

Contributing to 2 PhDs
James Buteau Louise Kostos
Arun Azad ProsTIC